The purpose of this research is to find out how a nasal spray (fluticasone furoate),
sometimes given to children with obstructive sleep apnea syndrome (OSAS), works on certain
cells within a child's adenoids. We hypothesize that intranasal steroids lead to an
upregulation of T regulatory cells in the adenoid tissues of children with OSAS. This will
result in a local reduction in inflammation and edema explaining the improvement in OSAS.
- Age: between 2 and 12 years
- Polysomnogram results showing AHI >5/hr irrespective of saturations
- No other significant medical problems except well controlled asthma
- No chronic medication intake except bronchodilators and leukotriene receptor
- No systemic steroids within the past month
- No intranasal steroids within the past 2 weeks
- Patients with OSAS who are overweight (BMI>95th percentile for age) or who have
neurological or craniofacial abnormalities as these tend to have OSAS related to
these factors per se.
- Females of the specified age group who have already had their first period.